The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | MANIFEST: ruxolitinib plus pelabresib for JAK-inhibitor naïve myelofibrosis
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, talks on the findings of a subgroup analysis of Arm 3 of the Phase II MANIFEST study (NCT02158858), investigating pelabresib in combination with ruxolitinib for patients with myelofibrosis who are JAK inhibitor-naïve. Pelabresib is a first-in-class, oral, small-molecule BET inhibitor. Dr Kremyanskaya reports that at 24 weeks, 67% of patients achieve a 35% reduction in spleen volume, with a median reduction of 50%. Pelabresib was generally well-tolerated. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Marina Kremyanskaya, MD, PhD, has participated in a consultancy role for Protagonist Therapeutics.
